These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34044856)

  • 1. Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.
    Ikeda M; Wakabayashi Y; Okamoto K; Yanagimoto S; Okugawa S; Moriya K
    AIDS Res Ther; 2021 May; 18(1):30. PubMed ID: 34044856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
    Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
    AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
    Schwarze-Zander C; Piduhn H; Boesecke C; Schlabe S; Stoffel-Wagner B; Wasmuth JC; Strassburg CP; Rockstroh JK
    HIV Med; 2020 Jul; 21(6):378-385. PubMed ID: 32065713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
    Kanda N; Okamoto K; Okumura H; Mieno M; Sakashita K; Sasahara T; Hatakeyama S
    HIV Med; 2021 Jul; 22(6):457-466. PubMed ID: 33720508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
    Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
    HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
    Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
    Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational Study.
    Moschopoulos CD; Protopapas K; Thomas K; Kavatha D; Papadopoulos A; Antoniadou A
    AIDS Res Hum Retroviruses; 2023 Feb; 39(2):68-75. PubMed ID: 36401506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.
    Tabak F; Zerdali E; Altuntaş O; Gunduz A; Bolukcu S; Mete B; Nakir IY; Kumbasar Karaosmanoglu H; Yildiz DS; Meric Koc M; Dokmetas İ;
    Int J STD AIDS; 2021 May; 32(6):562-569. PubMed ID: 33599173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
    Kauppinen KJ; Kivelä P; Sutinen J
    AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
    Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
    J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
    Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
    BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide Fumarate (TAF) in Hepatitis B/HIV Co-Infection: A Feasibility Study.
    Lok J; Veloz MFG; Byrne R; Carey I; Childs K; Agarwal K; Nelson M
    Clin Ther; 2024 Feb; 46(2):159-163. PubMed ID: 38143153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
    Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
    J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
    Martínez-Sanz J; Serrano-Villar S; Muriel A; García Fraile LJ; Orviz E; Mena de Cea Á; Campins AA; Moreno S
    Clin Infect Dis; 2023 Feb; 76(3):e652-e660. PubMed ID: 35903910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety.
    Petrakis V; Panagopoulos P; Papachristou S; Papanas N; Terzi I; Trypsianis G; Papazoglou D
    AIDS Res Hum Retroviruses; 2020 Sep; 36(9):697-702. PubMed ID: 32527142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
    Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
    Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017.
    Gomez M; Seybold U; Roider J; Härter G; Bogner JR
    Infection; 2019 Feb; 47(1):95-102. PubMed ID: 30269210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.